Future of Diabetes...What next for Gliptins
Dipeptidyl peptidase-4 (DPP-4) inhibitors, or gliptins, are a relatively new class of oral drugs for type 2 diabetes. These drugs block the DPP-4 enzyme metabolism of incretin hormones, including GLP-1 and GIP. In this issue of Diabetes News Nucleus, let us understand more about gliptins and the future of diabetes management with special focus on this new class of drugs.
More FAQs by
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article